• US FDA Approval

WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections

Shanghai, July 23, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit…

• Investment

Piramal Pharma Solutions Invests $10 million USD to Expand its High Potency API Capability in its Riverview Facility in U.S.

~ Expansion enhances the company’s ability to serve the growing ADC market ~  Michigan, June 21, 2019: Piramal Pharma Solutions (PPS),…

Twin USFDA Approvals for Morepen Labs’ Bulk Drugs (API) Facilities

Baddi facility gets US FDA nod for bulk drug “Atorvastatin” and Masulkhana facility for “Montelukast” New Delhi, August 05, 2018:…

• Archives

WuXi STA Changzhou Site Passes First U.S. FDA Inspection

The integrated R&D and manufacturing facility is expecting more products to go into commercial production post approval Shanghai, May 11,…

• Archives

Pre-Budget Expectations by Ms. Pushpa Vijayaraghavan, Director – Healthcare & Lifesciences advisory, Sathguru Management Consultants

New Delhi, February 01, 2018: Two changes will be critical for the pharma and biotech segments –  Innovation incentives –…